Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1977 1
1978 2
1979 2
1980 1
1981 1
1984 1
1985 3
1986 6
1987 15
1988 11
1989 7
1990 4
1991 6
1992 6
1993 7
1994 11
1995 6
1996 11
1997 6
1998 4
1999 4
2000 5
2001 8
2002 1
2003 4
2004 3
2005 2
2006 6
2007 3
2008 5
2009 4
2010 6
2011 7
2012 7
2013 6
2014 2
2015 10
2016 8
2017 15
2018 10
2019 9
2020 7
2021 9
2022 10
2023 11
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

268 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Cordtz R, De Cock D, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A. Lauper K, et al. Among authors: nordstrom dc. Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586. Epub 2022 Jun 15. Ann Rheum Dis. 2022. PMID: 35705376 Free PMC article.
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group. Østergaard M, et al. Among authors: nordstrom dc. Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. Ann Rheum Dis. 2023. PMID: 37423647 Clinical Trial.
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld A, Leeb BF, Rotar Z, Rodrigues A, Kristianslund EK, Kvien TK, Elkayam O, Lukina G, Bergstra SA, Finckh A, Courvoisier DS. Pombo-Suarez M, et al. Among authors: nordstrom dc. Ann Rheum Dis. 2023 Feb;82(2):175-181. doi: 10.1136/ard-2022-222835. Epub 2022 Sep 13. Ann Rheum Dis. 2023. PMID: 36100351
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA. Jaeckle KA, et al. Among authors: nordstrom dg. Neuro Oncol. 2021 Mar 25;23(3):457-467. doi: 10.1093/neuonc/noaa168. Neuro Oncol. 2021. PMID: 32678879 Free PMC article. Clinical Trial.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group. Hetland ML, et al. Among authors: nordstrom d. BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. BMJ. 2020. PMID: 33268527 Free PMC article. Clinical Trial.
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Michelsen B, Østergaard M, Nissen MJ, Ciurea A, Möller B, Ørnbjerg LM, Zavada J, Glintborg B, MacDonald A, Laas K, Nordström D, Gudbjornsson B, Iannone F, Hellmand P, Kvien TK, Rodrigues AM, Codreanu C, Rotar Z, Castrejón Fernández I, Wallman JK, Vencovsky J, Loft AG, Heddle M, Vorobjov S, Hokkanen AM, Gröndal G, Sebastiani M, van de Sande M, Kristianslund EK, Santos MJ, Mogosan C, Tomsic M, Díaz-González F, Di Giuseppe D, Hetland ML. Michelsen B, et al. Among authors: nordstrom d. Lancet Reg Health Eur. 2023 Aug 4;33:100706. doi: 10.1016/j.lanepe.2023.100706. eCollection 2023 Oct. Lancet Reg Health Eur. 2023. PMID: 37601339 Free PMC article. Review.
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Glintborg B, Di Giuseppe D, Wallman JK, Nordström DC, Gudbjornsson B, Hetland ML, Askling J, Grondal G, Sokka T, Provan SA, Michelsen B, Kristianslund EK, Dreyer L, Love TJ, Lindström U. Glintborg B, et al. Among authors: nordstrom dc. Ann Rheum Dis. 2023 Jun;82(6):820-828. doi: 10.1136/ard-2022-223650. Epub 2023 Feb 22. Ann Rheum Dis. 2023. PMID: 36813538
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R, Mongin D, Bergstra SA, Choquette D, Codreanu C, De Cock D, Dreyer L, Elkayam O, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Koca SS, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Strangfeld A, Verschueren P, Westermann R, Zavada J, Courvoisier DS, Finckh A, Lauper K. Aymon R, et al. Among authors: nordstrom dc. Ann Rheum Dis. 2024 Mar 12;83(4):421-428. doi: 10.1136/ard-2023-224670. Ann Rheum Dis. 2024. PMID: 38071508 Free PMC article.
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
Lend K, Koopman FA, Lampa J, Jansen G, Hetland ML, Uhlig T, Nordström D, Nurmohamed M, Gudbjornsson B, Rudin A, Østergaard M, Heiberg MS, Sokka-Isler T, Hørslev-Petersen K, Haavardsholm EA, Grondal G, Twisk JWR, van Vollenhoven R. Lend K, et al. Among authors: nordstrom d. Arthritis Rheumatol. 2024 Mar;76(3):363-376. doi: 10.1002/art.42730. Epub 2024 Jan 18. Arthritis Rheumatol. 2024. PMID: 37846618 Clinical Trial.
268 results